We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
-19.03%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$251M
AUM Growth
-$52.6M
Cap. Flow
+$11.6M
Cap. Flow %
4.61%
Top 10 Hldgs %
98.51%
Holding
13
New
2
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$5.03M
2
INZY
Inozyme Pharma
INZY
+$4.24M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.82M
4
IOBT
IO Biotech
IOBT
+$1.52M

Top Sells

Rank Stock Value
1
OCS icon
Oculis Holding
OCS
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$135M 53.75%
797,008
+15,000
+2% +$2.82M
PCVX icon
2
Vaxcyte
PCVX
$8.94B
$40.4M 16.13%
793,036
– –
OCS icon
3
Oculis Holding
OCS
$721M
$24.4M 9.73%
2,218,754
-162,442
-7% -$2.04M
INZY
4
DELISTED
Inozyme Pharma
INZY
$18.9M 7.53%
4,494,851
+833,333
+23% +$4.24M
RLYB icon
5
Rallybio
RLYB
$86.7M
$8.1M 3.23%
300,581
– –
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$3.3B
$5.87M 2.34%
1,105,309
– –
FUSN
7
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$4.06M 1.62%
1,560,982
– –
GRCL
8
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$3.96M 1.58%
+1,375,000
New +$5.03M
EXAI
9
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$3.48M 1.39%
770,500
– –
VIGL
10
DELISTED
Vigil Neuroscience
VIGL
$3.02M 1.21%
560,595
– –
BOLT icon
11
Bolt Biotherapeutics
BOLT
$6.82M
$1.97M 0.78%
94,573
– –
IOBT
12
DELISTED
IO Biotech
IOBT
$1.22M 0.49%
+864,197
New +$1.52M
ALGS icon
13
Aligos Therapeutics
ALGS
$43.1M
$555K 0.22%
29,729
– –

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q3 2023 Portfolio in Review

As of Q3 2023, Pivotal bioVenture Partners Investment Advisor held 13 positions worth $251M, down 17% from $303M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Pivotal bioVenture Partners Investment Advisor deployed $11.6M of net new capital in Q3 2023, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Gracell Biotechnologies Inc. American Depositary Shares: 1,375,000 shares worth $3.96M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Oculis Holding, an estimated $2.04M trimmed.

  • Pivotal bioVenture Partners Investment Advisor's largest Q3 2023 buy was Gracell Biotechnologies Inc. American Depositary Shares: 1,375,000 shares worth $3.96M.
  • Pivotal bioVenture Partners Investment Advisor added most to Inozyme Pharma in Q3 2023, an estimated $4.24M increase.
  • Pivotal bioVenture Partners Investment Advisor's biggest Q3 2023 reduction was Oculis Holding, cutting an estimated $2.04M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 99% of its $251M portfolio in Q3 2023.
  • Pivotal bioVenture Partners Investment Advisor opened 2 new positions and closed 0 in Q3 2023.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value fell 17% quarter-over-quarter to $251M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q3 2023, filed 13 Nov 2023.